New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
10:44 EDTRPRXRepros expects to report results for Phase 2 vaginal Proellex study in 1Q13
Sees fully enrolling 1 year Dexa study in Q1. Expects to request Androxal pre-NDA meeting with FDA for 1Q14 in 4Q13. Comments from slides that will be presented at the 2013 Biotech Showcase Conference.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement
March 16, 2015
14:54 EDTRPRXFDA accepting Androxal NDA can be catalyst for Repros, says Brean Capital
Subscribe for More Information
09:28 EDTRPRXRepros Therapeutics reports Q4 EPS (31c), consensus (34c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use